South Africa’s well being regulator SAHPRA stated on Thursday that it had authorised use of Merck’s Covid-19 therapy tablet molnupiravir.
SAHPRA added in a press release that Pfizer had submitted an utility for its Covid-19 tablet, Paxlovid, which was into consideration.
“The authorisation of molnupiravir for compassionate use affords additional remedy within the struggle in opposition to Covid-19,” SAHPRA’s Chief Govt Boitumelo Semete-Makokotlela stated.
SAHPRA stated molnupiravir was solely indicated to be used in sufferers aged 18 years and older. It authorised with situations the importation of a restricted amount of molnupiravir capsules for a interval of six months.